[{"edinetCode":"E22560","endDate":"2017\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":201.0,"averageTemporaryStaff":37.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":6406872.0,"sharesOwendPercent":0.4537,"outstandingShares":null,"numberOfSubsidiary":3.0,"bps":1087.63,"equityRatio":0.817,"cashAndCashEquivalents":6803006000.0,"assets":18788871000.0,"currentAssets":10275632000.0,"fixedAsset":8513239000.0,"tangibleFixedAssets":8075681000.0,"intangibleFixedAssets":47491000.0,"investmentAndOtherAssets":390066000.0,"liabilities":3404274000.0,"currentLiabilities":2236808000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":1167465000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":15384597000.0,"capitalStock":15219029000.0,"capital":581146000.0,"capitalSurplus":787535000.0,"accumulatedEarnings":13850369000.0,"treasuryStock":-21000.0,"valuationAndConversionAdjustments":138911000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":8294887000.0,"costOfSales":2713994000.0,"grossProfit":5580893000.0,"sgaExpenses":4025488000.0,"salaryAndBenefit":724865000.0,"depreciationAndSGA":null,"RDExpenses":276149000.0,"operatingIncome":1545405000.0,"nonOperatingIncome":70359000.0,"nonOperatingExpenses":208096000.0,"interestExpense":null,"ordinaryProfit":1407668000.0,"extraordinaryGain":134907000.0,"extraordinaryLoss":51544000.0,"incomeBeforeTax":1491031000.0,"incomeTaxes":441614000.0,"netIncome":1049416000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1049416000.0,"comprehensiveIncome":1011014000.0,"eps":76.45,"dilutedEps":75.81,"dividendPerShare":null,"per":24.76,"roe":0.074,"cashFlowFromOperatingActivities":2697614000.0,"depreciationAndCashflowFromOperatingActivities":444846000.0,"cashFlowFromInvestingActivities":-72298000.0,"cashFlowFromFinancialActivities":1249026000.0,"changesInCashAndCashEquivalents":3806191000.0,"列1":"asr","submitDate":"2017\/6\/29","stockCode":4574,"accountingYear":"第71期（自　平成28年４月１日　至　平成29年３月31日）","accountingYearStart":"2016\/4\/1","accountingYearEnd":"2017\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E22560","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":880,"settlementDate":"2022\/3\/31","submitterName":"大幸薬品株式会社","submitterNameEnglish":"TAIKO PHARMACEUTICAL CO., LTD.","submitterNameKana":"タイコウヤクヒンカブシキガイシャ","location":"吹田市内本町三丁目３４番１４号","industory":"医薬品","corporateNumber":2120000000000.0},{"edinetCode":"E22560","endDate":"2018\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":218.0,"averageTemporaryStaff":33.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":8471190.0,"sharesOwendPercent":0.595,"outstandingShares":null,"numberOfSubsidiary":3.0,"bps":1149.92,"equityRatio":0.8,"cashAndCashEquivalents":6547511000.0,"assets":20472752000.0,"currentAssets":11764060000.0,"fixedAsset":8708691000.0,"tangibleFixedAssets":7895290000.0,"intangibleFixedAssets":92219000.0,"investmentAndOtherAssets":721181000.0,"liabilities":4053186000.0,"currentLiabilities":2816207000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":1236979000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":16419565000.0,"capitalStock":16235544000.0,"capital":683130000.0,"capitalSurplus":889518000.0,"accumulatedEarnings":14662917000.0,"treasuryStock":-21000.0,"valuationAndConversionAdjustments":136371000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":9459366000.0,"costOfSales":2885892000.0,"grossProfit":6573473000.0,"sgaExpenses":4695423000.0,"salaryAndBenefit":754825000.0,"depreciationAndSGA":null,"RDExpenses":317054000.0,"operatingIncome":1857050000.0,"nonOperatingIncome":23350000.0,"nonOperatingExpenses":312495000.0,"interestExpense":null,"ordinaryProfit":1567905000.0,"extraordinaryGain":22270000.0,"extraordinaryLoss":37429000.0,"incomeBeforeTax":1552745000.0,"incomeTaxes":457786000.0,"netIncome":1094959000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1094959000.0,"comprehensiveIncome":1092420000.0,"eps":77.38,"dilutedEps":77.06,"dividendPerShare":null,"per":26.23,"roe":0.069,"cashFlowFromOperatingActivities":-59647000.0,"depreciationAndCashflowFromOperatingActivities":453657000.0,"cashFlowFromInvestingActivities":-113848000.0,"cashFlowFromFinancialActivities":-73943000.0,"changesInCashAndCashEquivalents":-255494000.0,"列1":"asr","submitDate":"2018\/6\/28","stockCode":4574,"accountingYear":"第72期（自　平成29年４月１日　至　平成30年３月31日）","accountingYearStart":"2017\/4\/1","accountingYearEnd":"2018\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E22560","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":880,"settlementDate":"2022\/3\/31","submitterName":"大幸薬品株式会社","submitterNameEnglish":"TAIKO PHARMACEUTICAL CO., LTD.","submitterNameKana":"タイコウヤクヒンカブシキガイシャ","location":"吹田市内本町三丁目３４番１４号","industory":"医薬品","corporateNumber":2120000000000.0},{"edinetCode":"E22560","endDate":"2019\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":229.0,"averageTemporaryStaff":27.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":9142494.0,"sharesOwendPercent":0.6374,"outstandingShares":null,"numberOfSubsidiary":3.0,"bps":1216.22,"equityRatio":0.808,"cashAndCashEquivalents":7192818000.0,"assets":21600191000.0,"currentAssets":12571893000.0,"fixedAsset":9028297000.0,"tangibleFixedAssets":7371497000.0,"intangibleFixedAssets":237630000.0,"investmentAndOtherAssets":1419169000.0,"liabilities":4114692000.0,"currentLiabilities":2826253000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":1288438000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":17485498000.0,"capitalStock":17338212000.0,"capital":776312000.0,"capitalSurplus":982700000.0,"accumulatedEarnings":15579225000.0,"treasuryStock":-25000.0,"valuationAndConversionAdjustments":107410000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":10418646000.0,"costOfSales":3215812000.0,"grossProfit":7202834000.0,"sgaExpenses":5131907000.0,"salaryAndBenefit":863143000.0,"depreciationAndSGA":null,"RDExpenses":410397000.0,"operatingIncome":2029926000.0,"nonOperatingIncome":66566000.0,"nonOperatingExpenses":211432000.0,"interestExpense":null,"ordinaryProfit":1885061000.0,"extraordinaryGain":228164000.0,"extraordinaryLoss":127242000.0,"incomeBeforeTax":1985983000.0,"incomeTaxes":570491000.0,"netIncome":1415491000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1415491000.0,"comprehensiveIncome":1386529000.0,"eps":98.99,"dilutedEps":98.88,"dividendPerShare":null,"per":18.98,"roe":0.084,"cashFlowFromOperatingActivities":1748182000.0,"depreciationAndCashflowFromOperatingActivities":460891000.0,"cashFlowFromInvestingActivities":-746807000.0,"cashFlowFromFinancialActivities":-338189000.0,"changesInCashAndCashEquivalents":645307000.0,"列1":"asr","submitDate":"2019\/6\/27","stockCode":4574,"accountingYear":"第73期（自　2018年４月１日　至　2019年３月31日）","accountingYearStart":"2018\/4\/1","accountingYearEnd":"2019\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E22560","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":880,"settlementDate":"2022\/3\/31","submitterName":"大幸薬品株式会社","submitterNameEnglish":"TAIKO PHARMACEUTICAL CO., LTD.","submitterNameKana":"タイコウヤクヒンカブシキガイシャ","location":"吹田市内本町三丁目３４番１４号","industory":"医薬品","corporateNumber":2120000000000.0},{"edinetCode":"E22560","endDate":"2019\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.837,"cashAndCashEquivalents":null,"assets":20217983000.0,"currentAssets":11265604000.0,"fixedAsset":8952378000.0,"tangibleFixedAssets":7315060000.0,"intangibleFixedAssets":246336000.0,"investmentAndOtherAssets":1390981000.0,"liabilities":3251107000.0,"currentLiabilities":1945607000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":1305500000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":16966875000.0,"capitalStock":16814837000.0,"capital":776312000.0,"capitalSurplus":982700000.0,"accumulatedEarnings":15323707000.0,"treasuryStock":-267883000.0,"valuationAndConversionAdjustments":112161000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":1416618000.0,"costOfSales":391069000.0,"grossProfit":1025549000.0,"sgaExpenses":843696000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":180853000.0,"nonOperatingIncome":2370000.0,"nonOperatingExpenses":55872000.0,"interestExpense":128000.0,"ordinaryProfit":127351000.0,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":127351000.0,"incomeTaxes":24266000.0,"netIncome":103084000.0,"netIncomeAttributableToOwnersOfTheParentCompany":103084000.0,"comprehensiveIncome":107836000.0,"eps":7.22,"dilutedEps":7.21,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2019\/8\/9","stockCode":4574,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E22560","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":880,"settlementDate":"2022\/3\/31","submitterName":"大幸薬品株式会社","submitterNameEnglish":"TAIKO PHARMACEUTICAL CO., LTD.","submitterNameKana":"タイコウヤクヒンカブシキガイシャ","location":"吹田市内本町三丁目３４番１４号","industory":"医薬品","corporateNumber":2120000000000.0},{"edinetCode":"E22560","endDate":"2019\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":8608526.0,"sharesOwendPercent":0.6106,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.829,"cashAndCashEquivalents":5977437000.0,"assets":20731317000.0,"currentAssets":11909178000.0,"fixedAsset":8822139000.0,"tangibleFixedAssets":7270046000.0,"intangibleFixedAssets":263884000.0,"investmentAndOtherAssets":1288208000.0,"liabilities":3500984000.0,"currentLiabilities":2180943000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":1320041000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":17230333000.0,"capitalStock":17106643000.0,"capital":788891000.0,"capitalSurplus":995279000.0,"accumulatedEarnings":15862326000.0,"treasuryStock":-539854000.0,"valuationAndConversionAdjustments":85115000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":4385494000.0,"costOfSales":1263003000.0,"grossProfit":3122491000.0,"sgaExpenses":2131660000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":980831000.0,"nonOperatingIncome":6539000.0,"nonOperatingExpenses":104947000.0,"interestExpense":237000.0,"ordinaryProfit":882423000.0,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":882423000.0,"incomeTaxes":240720000.0,"netIncome":641703000.0,"netIncomeAttributableToOwnersOfTheParentCompany":641703000.0,"comprehensiveIncome":619407000.0,"eps":45.19,"dilutedEps":45.16,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":78704000.0,"depreciationAndCashflowFromOperatingActivities":238935000.0,"cashFlowFromInvestingActivities":-100181000.0,"cashFlowFromFinancialActivities":-1168623000.0,"changesInCashAndCashEquivalents":-1215381000.0,"列1":"q2r","submitDate":"2019\/11\/8","stockCode":4574,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E22560","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":880,"settlementDate":"2022\/3\/31","submitterName":"大幸薬品株式会社","submitterNameEnglish":"TAIKO PHARMACEUTICAL CO., LTD.","submitterNameKana":"タイコウヤクヒンカブシキガイシャ","location":"吹田市内本町三丁目３４番１４号","industory":"医薬品","corporateNumber":2120000000000.0},{"edinetCode":"E22560","endDate":"2019\/12\/31","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.775,"cashAndCashEquivalents":null,"assets":24108199000.0,"currentAssets":15217803000.0,"fixedAsset":8890395000.0,"tangibleFixedAssets":7192875000.0,"intangibleFixedAssets":259178000.0,"investmentAndOtherAssets":1438342000.0,"liabilities":5399903000.0,"currentLiabilities":4071862000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":1328041000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":18708295000.0,"capitalStock":18604944000.0,"capital":865942000.0,"capitalSurplus":1072330000.0,"accumulatedEarnings":17206525000.0,"treasuryStock":-539854000.0,"valuationAndConversionAdjustments":72770000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":10092902000.0,"costOfSales":2553255000.0,"grossProfit":7539646000.0,"sgaExpenses":4255243000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":3203403000.0,"nonOperatingIncome":32605000.0,"nonOperatingExpenses":168981000.0,"interestExpense":325000.0,"ordinaryProfit":3067028000.0,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":3067028000.0,"incomeTaxes":940141000.0,"netIncome":2126887000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2126887000.0,"comprehensiveIncome":2092247000.0,"eps":149.92,"dilutedEps":149.75,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2020\/2\/10","stockCode":4574,"accountingYear":null,"accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E22560","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":880,"settlementDate":"2022\/3\/31","submitterName":"大幸薬品株式会社","submitterNameEnglish":"TAIKO PHARMACEUTICAL CO., LTD.","submitterNameKana":"タイコウヤクヒンカブシキガイシャ","location":"吹田市内本町三丁目３４番１４号","industory":"医薬品","corporateNumber":2120000000000.0},{"edinetCode":"E22560","endDate":"2020\/3\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":233.0,"averageTemporaryStaff":40.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":7803650.0,"sharesOwendPercent":0.5453,"outstandingShares":null,"numberOfSubsidiary":3.0,"bps":450.94,"equityRatio":0.76,"cashAndCashEquivalents":9645980000.0,"assets":25473752000.0,"currentAssets":16584007000.0,"fixedAsset":8889745000.0,"tangibleFixedAssets":7108392000.0,"intangibleFixedAssets":220416000.0,"investmentAndOtherAssets":1560936000.0,"liabilities":6099793000.0,"currentLiabilities":4794486000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":1305306000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":19373959000.0,"capitalStock":19264581000.0,"capital":1032471000.0,"capitalSurplus":1238859000.0,"accumulatedEarnings":17533104000.0,"treasuryStock":-539854000.0,"valuationAndConversionAdjustments":95032000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":14966165000.0,"costOfSales":4357793000.0,"grossProfit":10608371000.0,"sgaExpenses":6753792000.0,"salaryAndBenefit":855328000.0,"depreciationAndSGA":null,"RDExpenses":449380000.0,"operatingIncome":3824578000.0,"nonOperatingIncome":34260000.0,"nonOperatingExpenses":225801000.0,"interestExpense":394000.0,"ordinaryProfit":3633037000.0,"extraordinaryGain":600000.0,"extraordinaryLoss":129311000.0,"incomeBeforeTax":3504326000.0,"incomeTaxes":1050859000.0,"netIncome":2453466000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2453466000.0,"comprehensiveIncome":2441088000.0,"eps":57.57,"dilutedEps":57.34,"dividendPerShare":null,"per":27.03,"roe":0.133,"cashFlowFromOperatingActivities":3493291000.0,"depreciationAndCashflowFromOperatingActivities":495204000.0,"cashFlowFromInvestingActivities":-448486000.0,"cashFlowFromFinancialActivities":-581222000.0,"changesInCashAndCashEquivalents":2453161000.0,"列1":"asr","submitDate":"2020\/6\/26","stockCode":4574,"accountingYear":"第74期（自　2019年４月１日　至　2020年３月31日）","accountingYearStart":"2019\/4\/1","accountingYearEnd":"2020\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E22560","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":880,"settlementDate":"2022\/3\/31","submitterName":"大幸薬品株式会社","submitterNameEnglish":"TAIKO PHARMACEUTICAL CO., LTD.","submitterNameKana":"タイコウヤクヒンカブシキガイシャ","location":"吹田市内本町三丁目３４番１４号","industory":"医薬品","corporateNumber":2120000000000.0},{"edinetCode":"E22560","endDate":"2020\/6\/30","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.759,"cashAndCashEquivalents":null,"assets":27205507000.0,"currentAssets":17790196000.0,"fixedAsset":9415310000.0,"tangibleFixedAssets":7751015000.0,"intangibleFixedAssets":259760000.0,"investmentAndOtherAssets":1404534000.0,"liabilities":6536093000.0,"currentLiabilities":5221183000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":1314909000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":20669414000.0,"capitalStock":20568439000.0,"capital":1035425000.0,"capitalSurplus":1241813000.0,"accumulatedEarnings":18831054000.0,"treasuryStock":-539854000.0,"valuationAndConversionAdjustments":88032000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":5773908000.0,"costOfSales":1636503000.0,"grossProfit":4137405000.0,"sgaExpenses":1281913000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":2757491000.0,"nonOperatingIncome":6263000.0,"nonOperatingExpenses":61114000.0,"interestExpense":76000.0,"ordinaryProfit":2702639000.0,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":2702639000.0,"incomeTaxes":832262000.0,"netIncome":1870377000.0,"netIncomeAttributableToOwnersOfTheParentCompany":1870377000.0,"comprehensiveIncome":1863377000.0,"eps":43.56,"dilutedEps":43.28,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2020\/8\/12","stockCode":4574,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2021\/3\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E22560","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":880,"settlementDate":"2022\/3\/31","submitterName":"大幸薬品株式会社","submitterNameEnglish":"TAIKO PHARMACEUTICAL CO., LTD.","submitterNameKana":"タイコウヤクヒンカブシキガイシャ","location":"吹田市内本町三丁目３４番１４号","industory":"医薬品","corporateNumber":2120000000000.0},{"edinetCode":"E22560","endDate":"2020\/9\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":22316523.0,"sharesOwendPercent":0.5152,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.742,"cashAndCashEquivalents":8226025000.0,"assets":29782508000.0,"currentAssets":19417783000.0,"fixedAsset":10364724000.0,"tangibleFixedAssets":8488965000.0,"intangibleFixedAssets":300836000.0,"investmentAndOtherAssets":1574923000.0,"liabilities":7688042000.0,"currentLiabilities":6354502000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":1333540000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":22094465000.0,"capitalStock":22003747000.0,"capital":1148764000.0,"capitalSurplus":1516187000.0,"accumulatedEarnings":19819441000.0,"treasuryStock":-480646000.0,"valuationAndConversionAdjustments":86461000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":10967803000.0,"costOfSales":3138595000.0,"grossProfit":7829207000.0,"sgaExpenses":3441962000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":4238244000.0,"nonOperatingIncome":8840000.0,"nonOperatingExpenses":132102000.0,"interestExpense":113000.0,"ordinaryProfit":4114982000.0,"extraordinaryGain":null,"extraordinaryLoss":2851000.0,"incomeBeforeTax":4112130000.0,"incomeTaxes":1253366000.0,"netIncome":2858764000.0,"netIncomeAttributableToOwnersOfTheParentCompany":2858764000.0,"comprehensiveIncome":2850193000.0,"eps":66.29,"dilutedEps":65.95,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":100704000.0,"depreciationAndCashflowFromOperatingActivities":268325000.0,"cashFlowFromInvestingActivities":-1144145000.0,"cashFlowFromFinancialActivities":-367179000.0,"changesInCashAndCashEquivalents":-1419955000.0,"列1":"q2r","submitDate":"2020\/11\/12","stockCode":4574,"accountingYear":null,"accountingYearStart":"2020\/4\/1","accountingYearEnd":"2020\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E22560","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":880,"settlementDate":"2022\/3\/31","submitterName":"大幸薬品株式会社","submitterNameEnglish":"TAIKO PHARMACEUTICAL CO., LTD.","submitterNameKana":"タイコウヤクヒンカブシキガイシャ","location":"吹田市内本町三丁目３４番１４号","industory":"医薬品","corporateNumber":2120000000000.0},{"edinetCode":"E22560","endDate":"2020\/12\/31","Report abbreviation_x":"asr","context_x":"当期連結時点","numberOfEmployee":274.0,"averageTemporaryStaff":60.0,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":19863639.0,"sharesOwendPercent":0.4586,"outstandingShares":null,"numberOfSubsidiary":6.0,"bps":525.83,"equityRatio":0.717,"cashAndCashEquivalents":4698178000.0,"assets":31757696000.0,"currentAssets":19822138000.0,"fixedAsset":11935557000.0,"tangibleFixedAssets":9446643000.0,"intangibleFixedAssets":319129000.0,"investmentAndOtherAssets":2169784000.0,"liabilities":8976431000.0,"currentLiabilities":7487734000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":1488697000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":22781265000.0,"capitalStock":22693326000.0,"capital":1148764000.0,"capitalSurplus":1516187000.0,"accumulatedEarnings":20509020000.0,"treasuryStock":-480646000.0,"valuationAndConversionAdjustments":83682000.0,"Report abbreviation_y":"asr","context_y":"当期連結期間","Sales":17582989000.0,"costOfSales":5263129000.0,"grossProfit":12319859000.0,"sgaExpenses":6769871000.0,"salaryAndBenefit":771672000.0,"depreciationAndSGA":null,"RDExpenses":374809000.0,"operatingIncome":5650987000.0,"nonOperatingIncome":16067000.0,"nonOperatingExpenses":212615000.0,"interestExpense":282000.0,"ordinaryProfit":5454439000.0,"extraordinaryGain":null,"extraordinaryLoss":80169000.0,"incomeBeforeTax":5374270000.0,"incomeTaxes":1522711000.0,"netIncome":3851559000.0,"netIncomeAttributableToOwnersOfTheParentCompany":3851559000.0,"comprehensiveIncome":3840208000.0,"eps":89.18,"dilutedEps":88.82,"dividendPerShare":null,"per":18.08,"roe":0.183,"cashFlowFromOperatingActivities":-1516902000.0,"depreciationAndCashflowFromOperatingActivities":472871000.0,"cashFlowFromInvestingActivities":-2759700000.0,"cashFlowFromFinancialActivities":-649450000.0,"changesInCashAndCashEquivalents":-4947801000.0,"列1":"asr","submitDate":"2021\/3\/30","stockCode":4574,"accountingYear":"第75期（自　2020年４月１日　至　2020年12月31日）","accountingYearStart":"2020\/4\/1","accountingYearEnd":"2020\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E22560","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":880,"settlementDate":"2022\/3\/31","submitterName":"大幸薬品株式会社","submitterNameEnglish":"TAIKO PHARMACEUTICAL CO., LTD.","submitterNameKana":"タイコウヤクヒンカブシキガイシャ","location":"吹田市内本町三丁目３４番１４号","industory":"医薬品","corporateNumber":2120000000000.0},{"edinetCode":"E22560","endDate":"2021\/3\/31","Report abbreviation_x":"q1r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.767,"cashAndCashEquivalents":null,"assets":28609000000.0,"currentAssets":16128000000.0,"fixedAsset":12481000000.0,"tangibleFixedAssets":9878000000.0,"intangibleFixedAssets":367000000.0,"investmentAndOtherAssets":2235000000.0,"liabilities":6664000000.0,"currentLiabilities":5165000000.0,"shorTermDept":1000000000.0,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":null,"fixedLiabilities":1498000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":null,"netAsset":21944000000.0,"capitalStock":21778000000.0,"capital":1154000000.0,"capitalSurplus":1522000000.0,"accumulatedEarnings":19582000000.0,"treasuryStock":-480000000.0,"valuationAndConversionAdjustments":162000000.0,"Report abbreviation_y":"q1r","context_y":"当四半期累計期間連結期間","Sales":3271000000.0,"costOfSales":1271000000.0,"grossProfit":1999000000.0,"sgaExpenses":2197000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-190000000.0,"nonOperatingIncome":40000000.0,"nonOperatingExpenses":82000000.0,"interestExpense":0.0,"ordinaryProfit":-232000000.0,"extraordinaryGain":null,"extraordinaryLoss":null,"incomeBeforeTax":-232000000.0,"incomeTaxes":-85000000.0,"netIncome":-147000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-147000000.0,"comprehensiveIncome":-68000000.0,"eps":-3.39,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q1r","submitDate":"2021\/5\/7","stockCode":4574,"accountingYear":null,"accountingYearStart":"2021\/1\/1","accountingYearEnd":"2021\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E22560","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":880,"settlementDate":"2022\/3\/31","submitterName":"大幸薬品株式会社","submitterNameEnglish":"TAIKO PHARMACEUTICAL CO., LTD.","submitterNameKana":"タイコウヤクヒンカブシキガイシャ","location":"吹田市内本町三丁目３４番１４号","industory":"医薬品","corporateNumber":2120000000000.0},{"edinetCode":"E22560","endDate":"2021\/6\/30","Report abbreviation_x":"q2r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":19960491.0,"sharesOwendPercent":0.458,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.735,"cashAndCashEquivalents":5652000000.0,"assets":27209000000.0,"currentAssets":14625000000.0,"fixedAsset":12583000000.0,"tangibleFixedAssets":9568000000.0,"intangibleFixedAssets":351000000.0,"investmentAndOtherAssets":2663000000.0,"liabilities":7223000000.0,"currentLiabilities":2357000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":639000000.0,"fixedLiabilities":4866000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":3360000000.0,"netAsset":19986000000.0,"capitalStock":19818000000.0,"capital":1201000000.0,"capitalSurplus":1648000000.0,"accumulatedEarnings":17356000000.0,"treasuryStock":-388000000.0,"valuationAndConversionAdjustments":167000000.0,"Report abbreviation_y":"q2r","context_y":"当四半期累計期間連結期間","Sales":5106000000.0,"costOfSales":3655000000.0,"grossProfit":1451000000.0,"sgaExpenses":3763000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-2280000000.0,"nonOperatingIncome":42000000.0,"nonOperatingExpenses":499000000.0,"interestExpense":1000000.0,"ordinaryProfit":-2737000000.0,"extraordinaryGain":60000000.0,"extraordinaryLoss":225000000.0,"incomeBeforeTax":-2901000000.0,"incomeTaxes":-529000000.0,"netIncome":-2372000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-2372000000.0,"comprehensiveIncome":-2288000000.0,"eps":-54.62,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":-1259000000.0,"depreciationAndCashflowFromOperatingActivities":454000000.0,"cashFlowFromInvestingActivities":-1149000000.0,"cashFlowFromFinancialActivities":3305000000.0,"changesInCashAndCashEquivalents":954000000.0,"列1":"q2r","submitDate":"2021\/8\/6","stockCode":4574,"accountingYear":null,"accountingYearStart":"2021\/1\/1","accountingYearEnd":"2021\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E22560","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":880,"settlementDate":"2022\/3\/31","submitterName":"大幸薬品株式会社","submitterNameEnglish":"TAIKO PHARMACEUTICAL CO., LTD.","submitterNameKana":"タイコウヤクヒンカブシキガイシャ","location":"吹田市内本町三丁目３４番１４号","industory":"医薬品","corporateNumber":2120000000000.0},{"edinetCode":"E22560","endDate":"2021\/9\/30","Report abbreviation_x":"q3r","context_x":"当四半期会計期間連結時点","numberOfEmployee":null,"averageTemporaryStaff":null,"averageAge":null,"averageYearsOfService":null,"averageAnnualSalary":null,"sharesOwned":null,"sharesOwendPercent":null,"outstandingShares":null,"numberOfSubsidiary":null,"bps":null,"equityRatio":0.716,"cashAndCashEquivalents":null,"assets":28532000000.0,"currentAssets":16033000000.0,"fixedAsset":12498000000.0,"tangibleFixedAssets":9410000000.0,"intangibleFixedAssets":343000000.0,"investmentAndOtherAssets":2744000000.0,"liabilities":8108000000.0,"currentLiabilities":2650000000.0,"shorTermDept":null,"currentPortionOfBonds":null,"currentPortionOfLongTermDebt":889000000.0,"fixedLiabilities":5458000000.0,"bonds":null,"convertibleBond":null,"commercialPaper":null,"longTermDebts":3950000000.0,"netAsset":20423000000.0,"capitalStock":20243000000.0,"capital":1201000000.0,"capitalSurplus":1648000000.0,"accumulatedEarnings":17781000000.0,"treasuryStock":-388000000.0,"valuationAndConversionAdjustments":179000000.0,"Report abbreviation_y":"q3r","context_y":"当四半期累計期間連結期間","Sales":8355000000.0,"costOfSales":4571000000.0,"grossProfit":3783000000.0,"sgaExpenses":5405000000.0,"salaryAndBenefit":null,"depreciationAndSGA":null,"RDExpenses":null,"operatingIncome":-1578000000.0,"nonOperatingIncome":54000000.0,"nonOperatingExpenses":865000000.0,"interestExpense":3000000.0,"ordinaryProfit":-2389000000.0,"extraordinaryGain":60000000.0,"extraordinaryLoss":225000000.0,"incomeBeforeTax":-2553000000.0,"incomeTaxes":-605000000.0,"netIncome":-1947000000.0,"netIncomeAttributableToOwnersOfTheParentCompany":-1947000000.0,"comprehensiveIncome":-1851000000.0,"eps":-44.79,"dilutedEps":null,"dividendPerShare":null,"per":null,"roe":null,"cashFlowFromOperatingActivities":null,"depreciationAndCashflowFromOperatingActivities":null,"cashFlowFromInvestingActivities":null,"cashFlowFromFinancialActivities":null,"changesInCashAndCashEquivalents":null,"列1":"q3r","submitDate":"2021\/11\/9","stockCode":4574,"accountingYear":null,"accountingYearStart":"2021\/1\/1","accountingYearEnd":"2021\/12\/31","accountingStandards":"Japan GAAP","consolidatedAccounting":true,"edinetCode2":"E22560","organizationCategory":"内国法人・組合","listingClassification":"上場","consolidated":"有","capital3":880,"settlementDate":"2022\/3\/31","submitterName":"大幸薬品株式会社","submitterNameEnglish":"TAIKO PHARMACEUTICAL CO., LTD.","submitterNameKana":"タイコウヤクヒンカブシキガイシャ","location":"吹田市内本町三丁目３４番１４号","industory":"医薬品","corporateNumber":2120000000000.0}]